Bracco Diagnostic Imaging

What Bracco Diagnostic Imaging does

Bracco Diagnostic Imaging is the diagnostic imaging arm of the family-owned Bracco Group, headquartered in Milan, Italy, with approximately 4,000 employees and €2.2 billion in annual revenue. The company develops, manufactures, and markets contrast imaging agents (X-ray/CT iodinated agents, gadolinium-based MRI agents including the half-dose VUEWAY/gadopiclenol, and microbubble CEUS ultrasound agents), medical devices through its wholly-owned ACIST Medical Systems subsidiary (cardiovascular injectors, the FDA-cleared ACIST Pro Diagnostic System), and AI-enabled digital health software including the AiMIFY imaging analysis platform and CE-marked AI MRI software co-developed with Subtle Medical. Its portfolio also includes molecular imaging/nuclear medicine products and the BubbleGen streptavidin-conjugated microbubble platform for cell therapy manufacturing, supported by 2,500+ active patents and 11 global innovation centers with 8% of turnover reinvested in R&D.

The company sells to hospitals, radiology departments, cardiovascular cath labs, and cell therapy manufacturers across more than 24 countries in Europe, the Americas, and Asia, using a combination of direct field sales through regional subsidiaries, distributor partnerships in non-core geographies, and the Bracco Global Academy for clinical education. Revenue is generated primarily through hardware/agent sales (contrast agents and devices) with growing contribution from subscription/recurring digital health software and licensing/royalty streams tied to cell therapy technology. Key strategic alliances include a worldwide co-invention and shared-manufacturing collaboration with Guerbet on gadopiclenol, a multi-year Master Research Agreement with NYU Langone Health covering MRI, photon-counting CT, targeted ultrasound, and AI-enabled imaging, and the Subtle Medical AI software partnership. Recent corporate moves include the EU launch of AiMIFY, FDA clearance of ACIST Pro, Health Canada approval of VUEWAY, an upgrade of Geneva manufacturing for clinical-grade GMP cell therapy production, and historical acquisitions of Blue Earth Diagnostics (2019) and SurgVision (2017).

Name

Bracco Diagnostic Imaging

Legal name

Bracco

Website

https://braccoimaging.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Short description

Bracco Diagnostic Imaging is a family-owned, Italy-headquartered global developer and manufacturer of diagnostic imaging contrast agents, medical devices, and AI-enabled digital health software, serving hospitals, radiology departments, cath labs, and cell therapy manufacturers across more than 24 countries.

Ownership category

akta.pro rank

Product category

Diagnostic Imaging Agents & Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Contrast Media Injectors & Radiology Accessories (HLAHABAK)

akta.pro secondary industries

Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

Keywords

• Diagnostic imaging agents
• Medical contrast media
• Interventional cardiology devices
• Molecular imaging solutions
• AI imaging software

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Contrast Agents: Manufacture and sale of contrast imaging agents for X-ray/CT, MRI, and ultrasound procedures. Includes gadolinium-based agents, iodinated contrast agents, and microbubble ultrasound contrast agents.
2. Medical Devices: Sale of medical imaging devices including injectors, cardiovascular diagnostic systems, and imaging equipment through ACIST Medical Systems subsidiary.
3. Digital Health Solutions: AI-enabled imaging software and digital health solutions including AiMIFY platform for PET/CT and MRI analysis.
4. Cell Therapy Technology: Streptavidin-conjugated lipid-based microbubble technology for cell therapy workflows, with GMP manufacturing capabilities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Bracco Diagnostic Imaging develops, manufactures, and commercializes contrast imaging agents for X-ray/CT, MRI, and ultrasound procedures, along with interventional cardiology medical devices (via ACIST Medical Systems) and digital health/AI imaging software (AiMIFY). The company also offers cell therapy manufacturing technology (BubbleGen) based on proprietary lipid microbubble formulations. Products are sold globally to hospitals, radiology departments, and catheterization laboratories across more than 37 countries.

Product overview

Bracco Diagnostic Imaging is a comprehensive diagnostic imaging portfolio company offering a multi-modality platform of contrast agents, medical devices, and digital health solutions. The core portfolio includes X-ray/CT contrast agents, MRI contrast agents (featuring VUEWAY® gadopiclenol with reduced-dose technology), CEUS (Contrast Enhanced Ultrasound) using microbubble technology, Molecular Imaging/Nuclear Medicine products, Cardiovascular solutions through ACIST Medical Systems, and AI-powered digital health platforms (AiMIFY®). The company also operates in Cell Therapy through its BubbleGen platform. Bracco operates as an integrated platform with products spanning contrast media, medical devices, digital/AI solutions, and advanced manufacturing capabilities across 11 innovation centers worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• VUEWAY: Gadopiclenol MRI contrast agent product line
• AiMIFY
• ACIST Medical Systems
• BubbleGen

Products and services

• VUEWAY (gadopiclenol) Macrocyclic gadolinium-based MRI contrast agent that achieves effective imaging at half the standard dose (0.05 mmol/kg versus 0.1 mmol/kg), reducing gadolinium exposure for patients while maintaining diagnostic efficacy. Approved in 37 countries.
• AiMIFY AI-powered diagnostic imaging analysis platform providing advanced image analysis capabilities for medical imaging, supporting precision medicine applications.
• ACIST Pro Diagnostic System Advanced diagnostic system for catheterization and imaging procedures in cardiovascular applications, developed through ACIST Medical Systems (a Bracco company).
• BubbleGen Cell therapy platform technology using streptavidin-conjugated lipid-based microbubbles for cell selection and activation, offering a bead-free, column-free alternative to traditional magnetic bead methods.
• X-ray/CT Contrast Agents Iodinated contrast imaging solutions for X-ray and computed tomography (CT) diagnostics, part of Bracco's comprehensive contrast media portfolio.
• CEUS (Contrast Enhanced Ultrasound) Targeted ultrasound contrast imaging solutions using microbubble technology for enhanced diagnostic ultrasound procedures.
• Molecular Imaging / Nuclear Medicine Radiopharmaceutical and nuclear medicine imaging solutions for molecular diagnostics, supporting oncology and other specialty applications.
• AI-Powered MRI Software (Subtle Medical Collaboration) CE-marked AI-powered MRI image processing and enhancement software developed in collaboration with Subtle Medical, enabling accelerated imaging workflows and improved image quality.

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• NYU Langone HealthcoreStrategic or Co-development Partner · 20 April 2026Multi-year Master Research Agreement focusing on MRI, photon-counting CT, targeted ultrasound, and AI-enabled PET/CT and MRI analysis. Collaboration combines NYU Langone's clinical and academic excellence with Bracco's contrast imaging expertise to translate scientific discoveries into real-world healthcare applications for precision medicine.
• ACIST Medical SystemscoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026ACIST Medical Systems is a Bracco company that received U.S. FDA clearance for ACIST Pro Diagnostic System for cardiovascular imaging applications.
• Subtle MedicalcoreTechnology or Integration · 16 June 2025Obtained CE mark for AI-powered MRI software, integrating Subtle Medical's AI technology with Bracco's imaging portfolio for enhanced MRI image processing and analysis.
• GuerbetcoreStrategic or Co-development Partner · 1 December 2021Worldwide collaboration agreement for gadopiclenol co-invention and development. Both companies share manufacturing responsibilities under separate commercial brands - Bracco markets as VUEWAY, Guerbet under its own brand. Product approved in 37 countries with over 4 million patient doses administered.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Guerbet: Guerbet is a France-headquartered diagnostic imaging specialist that, like Bracco, develops and markets MRI, X-ray/CT, and interventional radiology contrast agents. It is Bracco's direct co-development partner on gadopiclenol (VUEWAY), making it the closest like-for-like competitor in contrast media.
• Lantheus Holdings: Lantheus is a US-listed radiopharmaceutical and diagnostic imaging company focused on molecular imaging agents for oncology and other specialty indications, directly overlapping Bracco's molecular imaging / nuclear medicine portfolio. Both companies monetize specialty diagnostic imaging agents into the same hospital radiology customers.
• Bracco Imaging (Blue Earth Diagnostics legacy): Blue Earth Diagnostics, a Bracco-acquired radiopharmaceutical business, competes in the molecular imaging agent space with products like Axumin and PyL. It is included as a self-reference point for Bracco's molecular imaging franchise rather than an external competitor.

Broad incumbents

• GE HealthCare: GE HealthCare is a global medical imaging incumbent selling CT, MRI, PET, ultrasound, and a contrast media injectors portfolio that competes head-to-head with Bracco's injector and contrast offerings. It also owns the imaging hardware on which Bracco's contrast agents are consumed, giving it bundled selling leverage Bracco lacks.
• Bayer (Radiology / contrast media): Bayer's radiology business markets iodinated X-ray contrast agents and MRI contrast agents, directly overlapping Bracco's X-ray/CT and MRI contrast portfolios. As a large diversified life sciences incumbent, Bayer competes on global scale, distribution, and bundled hospital contracts.
• Siemens Healthineers: Siemens Healthineers is one of the world's largest medical imaging OEMs, with CT, MRI, and molecular imaging systems plus an expanding contrast media and AI imaging software portfolio. It competes with Bracco both at the device layer (vs. ACIST) and increasingly at the contrast and AI software layers (vs. VUEWAY/AiMIFY).
• Philips Healthcare: Philips is a global imaging and image-guided therapy incumbent with a contrast media injectors portfolio and growing AI imaging software business. It competes with Bracco in injectors, interventional cardiology (vs. ACIST), and hospital radiology AI software.
• Fujifilm Healthcare: Fujifilm Healthcare is a broad medical imaging OEM offering CT, MRI, ultrasound, endoscopy, and contrast media products. As a regional incumbent with growing contrast and AI imaging capabilities, it competes with Bracco across multiple modalities in Asia, Europe, and the Americas.

Emerging players

• Subtle Medical: Subtle Medical is an AI imaging software company whose CE-marked MRI software is integrated into Bracco's AiMIFY platform. It is an emerging AI player adjacent to Bracco's core contrast franchise and a direct partner/competitor in the AI MRI workflow layer.
• Telix Pharmaceuticals: Telix is an emerging radiopharmaceutical company developing molecular imaging agents, particularly for prostate and renal oncology. It overlaps with Bracco's molecular imaging / nuclear medicine business and Blue Earth Diagnostics' PyL franchise, making it a credible emerging peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bracco-diagnostic-imaging

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bracco Diagnostic Imaging